Skip to main content

$0.075 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
5 June 2026 at 1:46pm
Register to track PAA and receive email alerts.

Phase IIb Dog Trial Achieves Interim Clinical Endpoints

StockBot

416,823 posts

PAA released this announcement to the ASX on 28 June 2021, 8:29. The announcement is marked as price sensitive, and is 2 page(s) in length and 447.83kb in size.

You can view all announcements from PAA and see how they appear on a price chart on the announcements page.

At the date of this announcement, PAA was 0.072% short sold according to ASIC data. It was ranked the 487th most shorted stock on the ASX. It remains ranked 492nd as of the latest reported data (11 October 2024).

Other Recent Announcements from PAA
Results of General Meeting 30 June 2023, 12:38
Trading Halt 30 June 2023, 9:48
General Meeting - Chairman Script 30 June 2023, 9:42
Phase IIb Dog Trial Achieves Interim Clinical Endpoints 28 June 2021, 8:29
PharmAust receives ethics approval for Phase I trial in MND 2 June 2021, 8:23
Dr Kim Agnew appointed Principal Investigator of dog trial 14 May 2021, 11:13
Appendix 4C and Quarterly Update 29 April 2021, 8:18
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track PAA and receive email alerts.